You are here

Press Release Archive

- Pfizer Invites Public to View and Listen to Webcast of Pfizer Participation at Healthcare Conference

(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a presentation by Pfizer Inc. Chairman and Chief Executive Officer Jeffrey B. Kindler at the 20th Annual Bear Stearns Health Care Conference on Monday, September 10th at 1:30p.m. Eastern Daylight Savings Time. To view and listen to the webcast, visit our web site homepage at and click on the “the 20th

- Patients Who Switched from Established Lipitor Therapy to Simvastatin Experienced a Significant 30 Percent Increase in Relative Risk of Cardiovascular Events or Death, New Observational Study Shows

(BUSINESS WIRE)--An observational study of a large United Kingdom primary care database showed that switching patients from Pfizer’s Lipitor® (atorvastatin calcium) Tablets to simvastatin was associated with a 30 percent increase in the relative risk of major cardiovascular events, including heart attacks, strokes and certain types of heart surgeries, or death compared to patients who remained on Lipitor therapy

- Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program

(BUSINESS WIRE)--Pfizer Inc (NYSE:PFE) and Bristol-Myers Squibb Company (NYSE:BMY) (“companies”) today announced that they have finalized a definitive agreement for the worldwide collaboration to research, develop and commercialize DGAT-1 inhibitors, a collaboration first announced on April 26, 2007. Pfizer’s DGAT-1 discovery program includes advanced pre-clinical compounds with potential applications for the

- Pfizer Names Frank A. D'Amelio Chief Financial Officer

(BUSINESS WIRE)--Pfizer today announced that Frank A. D’Amelio, a senior executive with almost three decades of extensive operating and financial experience at AT&T, Lucent Technologies and Alcatel-Lucent, including serving as both chief operating officer and chief financial officer at Lucent, will become Pfizer’s Senior Vice President and Chief Financial Officer effective in mid-September. Mr. D’Amelio, who is

- Pfizer's SelzentryTM (Maraviroc) Tablets, Novel Treatment for HIV, Approved by FDA

(BUSINESS WIRE)--Pfizer Inc announced today that the U.S. Food and Drug Administration (FDA) has approved SelzentryTM (maraviroc) tablets, the first in a new class of oral HIV medicines in more than 10 years. Selzentry blocks viral entry into white blood cells, significantly reducing viral load and increasing T-cell counts in treatment-experienced patients infected with a specific type of HIV. “There is a profound need for new

- Breast Cancer Guidelines Confirm Central Role of 'Switch Strategy'; Recommendations of St Gallen Panel Support Exemestane Indication

(BUSINESS WIRE)--Guidelines from the 2007 St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer, published today in the Annals of Oncology (, confirm the value of switching from tamoxifen to an aromatase inhibitor (AI), such as exemestane, for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.i Approximately 360,000 women in

- First Medication to Prevent and Treat Vomiting in Dogs Now Available by Prescription

(BUSINESS WIRE)--Pfizer Animal Health, a business of Pfizer Inc (NYSE: PFE), announced today that Cerenia™ (maropitant citrate), the first and only FDA-approved medication for the prevention and treatment of canine vomiting from a wide range of causes, including motion sickness, is now available by prescription in the United States. Vomiting is one of the most common reasons owners take their dogs to the veterinarian. According

- Spanish Court Rules in Pfizer's Favor, Upholds Lipitor Patent

(BUSINESS WIRE)--Pfizer Inc said today that a Spanish court has upheld the company's enantiomer patent covering the calcium salt of atorvastatin, the active ingredient in Lipitor. The Commercial Court of First Instance Number 4 in Barcelona, which issued the ruling, found a second patent covering a stabilized formulation that includes atorvastatin is invalid. The patents were challenged by generic manufacturer Ranbaxy

- Maraviroc Reduces HIV Viral Load in Treatment-Naive Patients, 48 Week Data Show

(BUSINESS WIRE)--Rates of virologic suppression in patients receiving Pfizer’s novel CCR5 antagonist, maraviroc, compared to efavirenz (EFV) were 70.6% vs. 73.1% for <400 copies/ml and 65.3% vs. 69.3% at <50 copies/ml in the full analysis set (FAS) study population (n= 360, maraviroc/ n= 361, efavirenz), according to a late breaker presentation at the International AIDS Society conference in Sydney, Australia. Increases in

- Pfizer Receives Positive Opinion from CHMP for Celsentri(R) (maraviroc) for Treatment-Experienced Patients Infected with CCR5-Tropic HIV-1

(BUSINESS WIRE)--Pfizer Inc announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) issued a positive opinion recommending marketing authorization for Celsentri® (maraviroc), the first CCR5 antagonist for use in combination with other antiretroviral agents for treatment-experienced adult patients where only CCR5-tropic virus is detectable. The CHMP’s positive

- Pfizer Announces First Occupant in its Science Incubator

(BUSINESS WIRE)-- Pfizer today announced its first occupant for the company’s Incubator – a new development where scientific entrepreneurs progress their ideas towards innovative treatments for serious diseases. Vaughn Smider MD, PhD, an assistant professor at The Scripps Research Institute, in La Jolla CA, will work to develop a unique technology to identify antibodies that might lead to new therapies. He will

- Pfizer Reports Second-Quarter 2007 Results, Reconfirms Full-Year 2007 and 2008 Financial Guidance and Updates Progress on Immediate Business Priorities

(BUSINESS WIRE)--Pfizer: ($ millions, except per-share amounts)           Second Quarter   Year to Date     2007  

- High Court in Dublin Rules in Pfizer's Favor in Patent Case, Lipitor Protected from Generic Competition until 2011

(BUSINESS WIRE)--Pfizer Inc said today that the High Court in Dublin, Ireland has ruled that the basic patent covering atorvastatin - the active ingredient in Lipitor - would be infringed by a competitor product from generics manufacturer Ranbaxy. The decision, which is subject to a possible appeal, prevents Ranbaxy from launching its drug before the basic Lipitor patent (Irish Patent Number 60014) expires in November 2011. “

- Pfizer Recommends Rejection of Mini-Tender Offer by TRC Capital Corporation

(BUSINESS WIRE)--Pfizer Inc (NYSE: PFE) has been notified of an unsolicited “mini-tender offer” by TRC Capital Corporation of Toronto (TRC) for TRC to purchase in cash up to four million shares, or approximately 0.057%, of the outstanding Pfizer common stock, at a price of $25.00 per share. TRC’s offer price of $25.00 per Pfizer share represents a 2.31% discount to the closing price on June 26, 2007, the day before the

- Crystal Trial Confirms Central Role of Irinotecan in Metastatic Colorectal Cancer

(BUSINESS WIRE)--Data presented for the first time in Europe reinforce the position of irinotecan as a key component of first line therapy in the management of patients with metastatic colorectal cancer (mCRC). Colorectal cancer is the most common cancer in Europe, and the third most common cancer worldwide. Each year, 138,000 Europeans die from the disease. However, colorectal cancer is preventable in most cases and highly

- Pfizer Declares a 29-cent Third-Quarter, 2007, Dividend

(BUSINESS WIRE)--The board of directors of Pfizer today declared a 29-cent third-quarter, 2007, dividend on the company's common stock, payable September 5, 2007, to shareholders of record at the close of business on August 10, 2007 Pfizer increased its quarterly dividend to 29 cents in the first quarter of 2007 as part of a series of actions the company is taking to enhance shareholder value. The third-quarter 2007 cash

- Pfizer Board of Directors to Initiate Face-to-Face Meetings with Company's Institutional Investors on Corporate Governance Policies and Practices

(BUSINESS WIRE)--Pfizer said today that members of its Board of Directors will invite its largest institutional shareholders to a meeting where they will have an opportunity to provide comments and perspective on the company’s governance policies and practices including executive compensation. Pfizer is the first company to initiate a regular meeting between its Board and institutional investors on governance. The Board will invite

- Pfizer Initiates Phase III Trial to Study Sunitinib Malate in Patients with Metastatic Colorectal Cancer

(BUSINESS WIRE)--Pfizer announced today the initiation of a Phase III clinical trial to evaluate the safety and efficacy of sunitinib malate, in combination with a standard chemotherapy regimen, in patients with metastatic colorectal cancer (mCRC) - cancer originating in the colon that has spread to other parts of the body. In addition, new data from a Phase I study being presented this week at the World Congress on Gastrointestinal

- Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke

(BUSINESS WIRE)--Pfizer announced today that Lipitor (atorvastatin calcium) Tablets 80 mg reduced the risk of stroke, coronary heart disease events and major coronary events in type 2 diabetes patients who had no known coronary heart disease but who had experienced a recent stroke or mini-stroke, compared with placebo. The results are from a new analysis of the landmark Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL)

- Exubera Demonstrated Pulmonary Safety with Blood Sugar Control in Three-Year Interim Analyses

(BUSINESS WIRE)--Results from three-year interim analyses of two ongoing long-term clinical trials showed that small mean declines in lung function in diabetes patients who took Exubera® (insulin human [rDNA origin]) Inhalation Powder reversed when Exubera was discontinued. Upon re-initiation of Exubera, lung function changes similar to first time users of Exubera were observed. The studies also showed that patients on an Exubera


Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.


Stock Quote Disclaimer

20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.


If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.